Drostanolone (Masteron)

Overview

Drostanolone, almost universally known by the brand name Masteron, is a derivative of dihydrotestosterone. Medically it played a role decades ago as an adjunct in advanced breast cancer — an application that has long been replaced by better-tolerated therapies. Today it exists only outside approved medicine.

In the bodybuilding context, it is used in preparation phases for hardness and definition. Its reputation as a "mild" compound is only partly justified: liver and kidneys remain largely untouched, but the lipid profile is affected more severely than by most injectable steroids. It is a good illustration that "mild" is not a property of a substance as a whole, but always applies to a specific organ system.

Mechanism of Action

Drostanolone is a modified form of DHT, the more potent metabolite of testosterone. It binds strongly to the androgen receptor and cannot be converted to estradiol by the aromatase enzyme — hence the absence of water retention, which is exactly the effect it is used for.

Two consequences follow from the DHT structure and are often overlooked. First, drostanolone additionally inhibits the aromatization of other substances in the cycle, which lowers estradiol beyond its own non-aromatizing nature. Second, it acts on hair follicles and the prostate via the same pathway responsible for androgenetic hair loss — and finasteride, which otherwise blocks that conversion, is ineffective here because drostanolone is already in the DHT-derived form.

The pronounced effect on HDL is characteristic of DHT derivatives as a class. It occurs through altered activity of hepatic lipase and is not offset by a moderate dose.

Typical Context

Drostanolone is used in preparation phases at already low body fat, typically alongside a testosterone base and over eight to twelve weeks. Two esters are common: propionate with a short half-life and correspondingly frequent injections, and enanthate with a longer interval.

The point most often misunderstood in practice: the visual effect depends on body fat, not on the dose. At fifteen percent body fat, drostanolone produces essentially no visible result — what is left is the side-effect profile. This is why it appears almost exclusively in the last weeks before a competition or a photo shoot.

Side Effects & Risks

• Severe drop in HDL, rise in LDL — the most pronounced risk of this substance
• Accelerated hair loss with a genetic predisposition, not preventable with finasteride
• Estradiol falling too low, with joint pain, reduced libido and flat mood
• Androgenic strain on the prostate
• Elevated blood pressure
• Suppression of natural testosterone production
• Acne, oily skin
• Moderate rise in hematocrit

Blood Work & Monitoring

• Lipid profile (LDL, HDL, triglycerides) — the key value here; baseline, mid-cycle and 6–8 weeks after
• Estradiol (sensitive) — beware of levels that are too low, not too high
• Blood pressure — measured at home
• PSA — from the appropriate age, for prostate monitoring
• Total/free testosterone — to check the base
• Hematocrit & hemoglobin
• Liver values (ALT, AST, GGT) — usually unremarkable, part of the baseline

Harm-Reduction Notes

• The lipid profile is the deciding factor: measure a baseline before starting, otherwise later values cannot be judged
• HDL recovers slowly — plan a genuine break rather than chaining cycles back to back
• Do not combine with an aromatase inhibitor without measuring; the risk here is estradiol that is too low
• Finasteride is not a solution for the hair-loss issue with this substance
• Only meaningful at low body fat; used at higher body fat it delivers risk without a visible result
• Sterile single-use needles, rotate injection sites; the short propionate ester means frequent injections